Joseph E. McClellan

Joe McClellan leads the company’s R&D functions, with overarching responsibility for bringing Alvotech’s biosimilar candidates to market. He is an insightful scientist and passionate leader, overseeing R&D operations across our sites in Iceland, Germany, Switzerland and the US. He brings with him an outstanding track record in drug development and 20 years of extensive industry experience driving forward R&D programs, while ensuring strategic and operational excellence.

Prior to joining Alvotech, Joe worked at Wyeth and Pfizer for 17 years and developed broad experience in all areas of biologic medicine development including biosimilars, innovator biologics, pharmaceutical science, clinical development, regulatory strategy and discovery research. In his last role, he held the position of Global Head of Biosimilars Development and was the asset team lead for Pfizer’s biosimilar infliximab, IXIFI. During Joe’s tenure leading biosimilar development at Pfizer, the company secured major market approvals for 6 unique biosimilar molecules and submitted applications for 2 additional unique biosimilars that were subsequently approved.

Joe earned a Ph.D. degree in Chemistry, with a focus in Analytical Chemistry and Mass Spectrometry, from the University of Florida. In addition, he was a Postdoctoral Fellow in Mass Spectrometry and Analytical Biochemistry at the Boston University School of Medicine and received his MBA, with a focus on innovation and business growth in high-technology industries, from Northeastern University. He holds a Bachelor of Arts in Chemistry from the College of the Holy Cross.